文献速递血液净化与透析

医疗保险捆绑支付政策对血液透析成人贫血治疗、主要不良心血管事件及死亡率的影响

Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-05-19

该回顾性队列研究利用美国肾脏数据系统2006年1月1日至2016年12月31日数据,分析医疗保险捆绑支付及FDA促红细胞生成素刺激剂标签修订前后贫血治疗与临床结局。结果发现政策后促红细胞生成素刺激剂使用减少、血红蛋白>11 g/dl比例下降,主要不良心血管事件、卒中、全因死亡、心血管死亡和心力衰竭风险降低,但急性心肌梗死风险升高。

要点

  • 政策实施后促红细胞生成素刺激剂使用立即减少84.8/1000人(P<0.001),输血使用2012年4月快速增加8.34/1000人后逐渐下降。
  • 血红蛋白>11 g/dl患者比例从2006年1月68%降至2016年12月28%,血红蛋白<9 g/dl比例从5%升至9%。
  • 政策后主要不良心血管事件(调整HR 0.95,95%CI 0.94-0.96)、卒中(0.83,0.80-0.86)、全因死亡(0.87,0.86-0.89)、心血管死亡(0.81,0.79-0.83)和心力衰竭(0.86,0.84-0.88)风险降低,急性心肌梗死风险升高(1.04,1.01-1.06)。

核心结论

  • 医疗保险报销政策及FDA推荐的促红细胞生成素刺激剂剂量变化与促红细胞生成素刺激剂使用减少和血红蛋白水平降低相关。
  • 贫血治疗的变化与主要不良心血管事件、卒中、死亡和心力衰竭风险降低相关,但与急性心肌梗死风险升高相关。

研究设计与样本

  • 回顾性队列研究,使用美国肾脏数据系统2006年1月1日至2016年12月31日数据,纳入481,564例接受血液透析的医疗保险参保成人。
  • 比较政策前(2006-2010年)与政策后(2012-2016年)实施情况,采用中断时间序列和Cox比例风险回归模型。

主要发现

  • 促红细胞生成素刺激剂使用立即减少84.8/1000人(P<0.001),趋势线斜率显著下降(均P=0.001)。
  • 输血使用在2012年4月快速增加8.34/1000人,随后逐渐下降(均P=0.001)。
  • 血红蛋白>11 g/dl患者比例从2006年1月68%降至2016年12月28%,血红蛋白<9 g/dl比例从5%升至9%。
  • 政策后总体主要不良心血管事件调整HR 0.95(95%CI 0.94-0.96)、卒中调整HR 0.83(95%CI 0.80-0.86)、全因死亡调整HR 0.87(95%CI 0.86-0.89)、心血管死亡调整HR 0.81(95%CI 0.79-0.83)、心力衰竭调整HR 0.86(95%CI 0.84-0.88)风险均降低。
  • 急性心肌梗死风险升高,调整HR 1.04(95%CI 1.01-1.06)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In 2011, the Centers for Medicare & Medicaid Services implemented bundling of all services for patients receiving dialysis, including erythropoietin-stimulating agents use, and the Food and Drug Administration recommended conservative erythropoietin-stimulating agent dosing. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective cohort study investigated anemia care and clinical outcomes before and after the Centers for Medicare & Medicaid Services bundled payment and the revised Food and Drug Administration-recommended erythropoietin-stimulating agent labeling for Medicare-insured adults receiving hemodialysis using data from the United States Renal Data System from January 1, 2006 to December 31, 2016. Clinical outcomes included major adverse cardiovascular event (stroke, acute myocardial infarction, and all-cause mortality), cardiovascular mortality, and heart failure. Measurements were compared between prepolicy (2006-2010) and postpolicy (2012-2016) implementation using interrupted time series and Cox proportional hazards regression models. RESULTS: Of 481,564 patients, erythropoietin-stimulating agent use immediately decreased by 84.8 per 1000 persons (P<0.001), with a significant decrease in the slope of the trend line (both P=0.001). Blood transfusion use rapidly increased by 8.34 per 1000 persons in April 2012 and then gradually decreased (both P=0.001). The percentage of patients with hemoglobin >11 g/dl decreased from 68% in January 2006 to 28% in December 2016, whereas those with hemoglobin <9 g/dl increased from 5% to 9%. Overall major adverse cardiovascular event (adjusted hazard ratio, 0.95; 95% confidence interval, 0.94 to 0.96), stroke (adjusted hazard ratio, 0.83; 95% confidence interval, 0.80 to 0.86), all-cause mortality (adjusted hazard ratio, 0.87; 95% confidence interval, 0.86 to 0.89), cardiovascular mortality (adjusted hazard ratio, 0.81; 95% confidence interval, 0.79 to 0.83), and heart failure (adjusted hazard ratio, 0.86; 95% confidence interval, 0.84 to 0.88) risks were lower. Acute myocardial infarction risk (adjusted hazard ratio, 1.04; 95% confidence interval, 1.01 to 1.06) was higher after policies changed. CONCLUSIONS: The Medicare reimbursement policy and Food and Drug Administration-recommended erythropoietin-stimulating agent dosing changes were associated with lower erythropoietin-stimulating agent use and lower hemoglobin levels. These changes in anemia care were associated with lower risks of major adverse cardiovascular event, stroke, mortality, and heart failure but higher risk of acute myocardial infarction among adults receiving hemodialysis.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Park H, Desai R, Liu X, et al. Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis. Clin J Am Soc Nephrol. 2022. PMID: 35589388. doi:10.2215/CJN.14361121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。